

1 **Factors associated with onchocerciasis transmission after 20 years of community**
2 **treatment with ivermectin in savanah and forest areas in Central African Republic : A**
3 **Cross Sectional Study**

4

5

6 **Sylvain Honoré Woromogo^{1,2*}¶, Stéphanie Inesse Garoua-Adjou^{1¶}, Ange Donatien Ben**
7 **Ngouyombo^{1¶}, Rodrigue Herman Doyama-Woza^{2¶}, Henri Saint Calvaire Diemer^{2¶}, Jean**
8 **de Dieu Longo^{2¶}**

9 ¹Doctoral School of Human and Veterinary Sciences, University of Bangui, Central African
10 Republic

11 ²Department of Public Health, Faculty of Health Sciences, University of Bangui, Central
12 African Republic

13

14

15 ***Corresponding author:**

16 **Dr. Sylvain Honore WOROMOGO**

17 Doctoral School of Human and Veterinary Sciences, University of Bangui, Central African
18 Republic

19 Phone (or Mobile) No.: +236 74 42 26 36

20 Email: woromogos@gmail.com

21

22

23 ¶ These authors contributed equally to this work.

24

25

26

27

28

29

30

31

32

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35 The Central African Republic has endemic onchocerciasis in 20 health districts in savannah and
36 forest areas. The country organised a mass distribution campaign of ivermectin in 2023
37 through the National Onchocerciasis Control Programme. The objectives of this study were to
38 identify factors of persistent transmission of onchocerciasis. A cross-sectional study was carried
39 out in Bossangoa (savannah area) and Kémo (forest area) health districts. Using kelsey' formula
40 1600 respondents were recruited. Dependent variable is onchocerciasis status. Bivariate
41 analysis was carried out to determine the differential risks for onchocerciasis infection, each
42 variable being taken separately. The strength of statistical associations was measured by
43 prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals.
44 Onchocerciasis prevalence is 26.45% in Bossangoa (95% CI = 23.76 - 29.14), and 14.79%
45 (84/568) in Kémo (95% CI = 23.53 - 29.37). In both savannah and forest areas, the common
46 factors incriminated in the transmission of onchocerciasis after several years of community
47 distribution of ivermectin are: young age (PR = 2.44 (1.97 – 3.03), $p < 0.001$; 3.63 (2.32 –
48 5.70), $p < 0.001$ respectively), not taking ivermectin (PR = 2.31 (1.86 – 2.87), $p < 0.001$; 6.84
49 (4.42 – 10.57), $p < 0.001$ respectively), male sex (PR = 2.54 (2.04 – 3.16), $p < 0.001$; 1.79 (1.19
50 – 2.69), $p = 0.002$ respectively), living near rivers and in rural areas. Despite efforts, the
51 prevalence of onchocerciasis remains high in the 2 districts. The main factors incriminated in
52 the persistence of transmission are failure to take ivermectin, male sex and young age. The
53 National Onchocerciasis Control Programme needs to review its planning of activities,
54 ensuring that the population is constantly made aware before drugs are distributed, and
55 increasing the number of days of community-based distribution in order to improve therapeutic
56 coverage.

57 **Key words** : Burden, Transmission, Factors, Onchocerciasis, Savannah, Forest

58

59

60

61

62

63

64 **Synopsis**

65 Onchocerciasis is a disease called River Blindness and transmitted by the bites of infected
66 blackflies that reproduction is in high-flow streams. This disease affects the skin (itching and
67 nodules) and eyes (redness and even blindness). An effective treatment is ivermectin. Human
68 activities near rivers contribute to the disease. Also, good coverage of ivermectin intake by
69 the population considerably reduces the number of people affected. The question we asked
70 ourselves was: why, after more than 20 years of community-based distribution of ivermectin
71 in the Central African Republic, is onchocerciasis still being transmitted? The Central African
72 Republic has made considerable efforts to combat onchocerciasis despite the war, but the
73 number of people infected remains high. The study showed that in both the savannah and the
74 forest, men are particularly at risk, not only because of their activities near rivers, but also
75 because they do not protect their bodies as women do. We found a higher number of people
76 affected in rural areas than in urban areas. In the community that adheres to ivermectin use,
77 the number of people affected decreases. We recommended that the national onchocerciasis
78 control programme take into account the habits of the population in order to plan and monitor
79 their control activities (for example: increase the number of days ivermectin is distributed,
80 and the number of days community awareness is raised).

81

82

83

84

85

86

87

88

89

90

91

92

93 **Introduction**

94 Onchocerciasis or river blindness is a parasitic disease caused by the threadworm *Onchocerca*
95 *volvulus* (1). This worm is transmitted to humans by the bites of infected simuliids (or black
96 flies) and reproduces in high-flow streams (rivers). The adult worm produces embryonic larvae
97 (microfilariae) in the human body, which migrate into the skin, eyes and other organs. When a
98 female black fly bites an infected person to feed on their blood, it also absorbs microfilariae
99 which reproduce in the black fly and are then transmitted to other humans who are bitten (2).

100 Onchocerciasis leads to eye and skin complications (3). A genuine public health problem in
101 terms of morbidity, onchocerciasis is observed in three WHO regions: the African Region, the
102 American Region and the Eastern Mediterranean Region. In Africa, onchocerciasis affects
103 twenty-seven countries, and more than 99% of infected people live in sub-Saharan Africa (4).
104 According to the global burden of disease study estimate, there were 20.9 million *O.volvulus*
105 infections worldwide in 2017; 14.6 million of the infected people had skin disease and 1.15
106 million had vision loss (5,6). From a socio-economic point of view, although the impact of the
107 infestation on longevity is controversial, a study carried out in the West African savannah
108 showed a 13-year reduction in the life expectancy of blind people compared with non-blind
109 people (2). Some of the consequences of this disease on the lives of people in endemic areas
110 remain a cause for concern (3,4,7–9).

111 Treatment of individuals with ivermectin for 10 to 15 years through Mass Drug Administration
112 (MDA) programs annually or biannually was suggested by the African Program for
113 Onchocerciasis Control (APOC) as a means for disease elimination because the ivermectin
114 kills the microfilaria but only partly paralyzes the adult worm, and must be taken for the
115 reproductive lifespan of the worm to counteract transmission (10). APOC ended in 1995, and
116 individual countries were responsible for ensuring disease elimination (11). In the African
117 region, treatment increased from 119 million in 2015 to 132 million in 2016, and therapeutic
118 coverage rose from 64% to 67% (4).

119 The Central African Republic (CAR) has endemic onchocerciasis in 20 health districts in
120 savannah and forest areas. Supported by several partners, the country has organised a mass
121 distribution campaign of ivermectin in 2023 through the National Onchocerciasis Control
122 Programme (PNLOC). One year after this campaign, we wanted to measure the prevalence of
123 the disease in 2 health districts, one in the savannah zone and the other in the forest zone, and
124 to identify the factors that transmit the disease, with the aim of helping to reduce morbidity due
125 to this Neglected Tropical Disease (NTD).

126 **Methods**

127 **Study setting**

128 The study was conducted in 2 endemic health districts in the Central African Republic:
129 Bossangoa in the savannah zone and Kémo in the forest zone. These 2 health districts are
130 bordered by rivers with confluences, with a total population of 175,679 and 193,044
131 respectively. The main activities in common in these 2 areas are trade, agriculture, breeding,
132 hunting and other informal activities. We chose these 2 districts because a mass ivermectin
133 distribution campaign was organised in 2023, with therapeutic coverage of 45% and 81%
134 respectively in Bossangoa and Kémo. Furthermore, members of the management team in these
135 2 health districts received training in the diagnosis of Neglected Tropical Diseases in the same
136 year, with the support of partners (WHO, cbm and MDP).

137 **Study design and participants**

138 We conducted a cross-sectional analytical study from 4 January to 30 March 2024. Participants
139 were residents of Bossangoa and Kémo health districts. Anyone over 5 years of age who had
140 been resident in the locality for at least one year and who agreed to take part in the study was
141 included. Participants under 5 years of age, those who had been resident for less than a year and
142 those who refused to take part in the study were excluded. Anyone over 5 years of age who had
143 been resident in the locality for at least one year and who agreed to take part in the study was
144 included. Participants under 5 years of age, those who had been resident for less than a year and
145 those who refused to take part in the study were excluded. For participants under the age of 15,
146 verbal parental consent is required. The WHO recommends including children under the age of
147 10, believing that this is the best way to assess active transmission of the infection (12).

148 **Sampling**

149 The sample size for this study was determined using Kelsey's formula in STAC Calc from
150 EPIInfo for an observational study, for a power of 80%, a ratio of unexposed to exposed of 2
151 and a 95% confidence interval.(13). Considering a non-response rate of 10%, the final sample
152 size is 1600 participants.

153 We used a cluster survey to obtain respondents. The clusters were formed from a list of all the
154 villages and neighbourhoods in each health district. This gave us 30 clusters per health district.
155 For each cluster selected, all eligible participants were included in the study. In order to get as
156 many respondents as possible in a cluster or village, awareness-raising sessions were held with

157 village chiefs a week before the survey date. On the survey day, the team explained the purpose
158 of the study to each participant in an information note and obtained informed consent, which
159 was read and signed before the questionnaire was administered, followed by a clinical
160 examination and skin samples.

161 **Variables**

162 The dependent variable was the presence or absence of onchocerciasis. For this study we
163 collected as independent variables i) sociodemographic data (age, sex, occupation, activities,
164 residence, duration of residence of respondents, ii) clinical and medical data (skin and eye
165 characteristics, duration of signs, ivermectin intake).

166 **Data collection and tools**

167 A structured questionnaire, pre-tested in another health district and validated, was used to
168 collect data. It was administered in French and Sango (CAR's other national language) by
169 members of the district team, 6th year medical students and 3rd year nursing students. Members
170 of the health district team who had been trained in onchocerciasis diagnosis briefed the other
171 investigators.

172 Prevalence of onchocerciasis is determined by individual and community diagnosis. For
173 individual diagnosis, a skin sample (bloodless skin biopsy) is taken and examined for
174 microfilariae, and experienced investigators have used a slit lamp to look for microfilariae in
175 the eye. Dermal microfilariae were detected by examination of the bloodless skin biopsy using
176 Holth 2.3 mm snip forceps. Two samples were collected from the iliac crests, one on the right,
177 the other on the left, and then placed in the wells of a microtiter plate after adding a drop of
178 distilled water. Then the plates covered with parafilm paper. The samples were read within 24
179 hours of incubation.

180 Community diagnosis is epidemiological: symptoms of the disease in skin and eyes. For the
181 questions analyzing skin changes, any positive reports from the respondents were checked
182 clinically and confirmed by the interviewer. For epilepsy and seizures, the inter-viewer made
183 sure the definition of the condition was clear to the respondent, describing the disease in simple
184 words and with example. Diagnosed respondents are treated.

185 **Data analysis**

186 Anonymised data were entered into an Excel® file and analysed using EpiInfo™ software
187 version 3.5.1. Independent and dependent variables were summarized using descriptive

188 statistics, which were reported as frequencies and proportions for qualitative variables and mean
189 with standard deviation for quantitative variables. The chi-square test was used to compare
190 categorical variables with a significance level of $p < 0.05$.

191 For each variable taken separately, the results were first given according to the onchocerciasis
192 status. Thereafter, bivariate analysis was carried out to determine the differential risks for
193 onchocerciasis infection, each variable being taken separately. The strength of statistical
194 associations was measured by prevalence rates (PR) from log-binomial regression model and
195 their 95% confidence intervals.

196 **Ethical considerations**

197 The study protocol was validated by the Ethics Committee of the Faculty of Health Sciences of
198 the University of Bangui (« CSCVPER ») (agreement UB/-FACSS/CSCVPER). Each
199 participant read and understood the information note for the study. Signed informed consent
200 was obtained from each respondent. Formal written consent was obtained from the
201 parents/guardian for children under the age of 18. Finally, all respondents received a
202 commitment that their data would be anonymised.

203 **Results**

204 **Baseline characteristics of respondents**

205 Of the 1600 respondents, 1032 were from Bossangoa health district and 568 from Kémo health
206 district. The average age of participants was 31.22 years (± 6.46). More than half of the
207 respondents work in the informal sector (fishing, hunting, agriculture, etc.). At least 60% of
208 participants lived in rural areas and just under half lived along rivers (763/1600). Some
209 respondents acknowledged that they had not taken ivermectin during the last distribution
210 campaign (610/1600). Table 1 shows the other characteristics of the participants.

211 **Prevalence and symptoms of onchocerciasis among respondents**

212 Among the 1600 respondents examined, 357 had onchocerciasis, representing a prevalence of
213 22.31% (95% CI = 20.27 - 24.35). At health district level, this prevalence is 26.45% (273/1032)
214 in Bossangoa (95% CI = 23.76 - 29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53 -
215 29.37). The signs and symptoms of onchocerciasis observed among respondents are presented
216 in Table 2.

217 **Ivermectin uptake and onchocerciasis status**

218 Onchocerciasis is common in children aged between 5 and 14 and in the 15-34 age group in
219 our context. Of the 367 men taking ivermectin in 2023, 208 (56.67%) were positive for
220 onchocerciasis (compared with 23.92% of women). Among respondents who had taken
221 ivermectin in a single year, 44.63% (291/652) were positive for onchocerciasis, whereas among
222 those who had taken ivermectin for more than 2 years, 19.53% (66/338) were positive. A
223 significant association was found between not taking ivermectin and positive onchocerciasis
224 status ($p < 0.001$)(Table 3).

225 **Factors associated of transmission**

226 In both savannah and forest areas, the common factors incriminated in the transmission of
227 onchocerciasis after several years of community distribution of ivermectin are: young age (PR
228 = 2.44 (1.97 – 3.03), $p < 0.001$; 3.63 (2.32 – 5.70), $p < 0.001$ respectively), not taking
229 ivermectin (PR = 2.31 (1.86 – 2.87), $p < 0.001$; 6.84 (4.42 – 10.57), $p < 0.001$ respectively),
230 male sex (PR = 2.54 (2.04 – 3.16), $p < 0.001$; 1.79 (1.19 – 2.69), $p = 0.002$ respectively), living
231 near rivers and in rural areas. In forested areas, profession plays no role in onchocerciasis
232 transmission, and living in a rural environment appears to protect against onchocerciasis
233 transmission (PR = 0.33 (0.21 - 0.50), $p < 0.001$) (Tables 4 and 5).

234 **Discussion**

235 **The relevance of the study**

236 Neglected tropical diseases in general, and onchocerciasis in particular, are a real public health
237 concern, not only because of their persistent prevalence, but also because of their gravity, since
238 millions of infected people have a disability-adjusted life years (14). It is in this context that
239 countries have benefited from the support of numerous partners such as WHO which published
240 NTD Roadmap for 2021–2030 for elimination of transmission (EOT) for onchocerciasis, with
241 12 countries (including CAR) proposed to be verified for EOT by 2030 (15). A number of
242 statements supported this vision (16–19).

243 The CAR has signed up to these declarations and has an obligation to achieve results, as the
244 selected indicators for SDG 3 include those relating to NTDs, particularly target 3.3.
245 Onchocerciasis in CAR has long been considered a curse, especially in the town of Bossangoa,
246 which is reputed to be host to a record number of blind people due to onchocerciasis. The town's
247 beggars are precisely these blind people, despite receiving aid from charitable associations.

248 This study showed that the population is young and needs to be protected : average age of was
249 31.22 years (\pm 6.46). Several authors reported the same trends (20–22). Over 60.69% (671
250 /1600) of the population studied live in rural areas and 38.12% (610/1600), which means that
251 strategies need to be developed to reach people in remote areas.

252 **Real burden as neglected tropical disease**

253 Despite several years of efforts to combat onchocerciasis, prevalence remains high in these 2
254 districts (22.31% [95% CI = 20.27 - 24.35] in Bossangoa district and 14.79% [95% CI = 23.53
255 - 29.37] in Kémo district. whereas in Cameroon this prevalence is relatively low, varying from
256 1.5 to 6% (23), and Guinea, which will be ready for 2030 (24). WHO recommends that countries
257 eliminate onchocerciasis with a prevalence of 0.1% (11). The Central African Republic is one
258 of the countries that have made progress in onchocerciasis control and elimination (11,14), but
259 more needs to be done if it is to meet the 2030 target. The country's nationwide civil war since
260 2013 has had a detrimental effect on the elimination of onchocerciasis. Some studies have
261 pointed to this aspect (11). Participants examined showed the classic signs of skin and eye
262 damage, with an impressive number of blind people (401 in total). A number of respondents,
263 99/600 (6.19) have onchocerciasis-associated epilepsy (OAE) status. Similar proportions were
264 observed in the Democratic Republic of Congo and South Sudan (25,26). This may explain the
265 high density of microfilariae in the body. These people may be stigmatised by the public, which
266 could prevent them from being married (27).

267 **Transmission factors**

268 The prevalence was significantly higher in men compared to women and was associated with
269 younger age groups. The particularity of the Kémo health district is that this difference is not
270 significant for the 15-34 age group. In this district, secondary school instructors take part in the
271 distribution of ivermectin in schools. In any event, this study showed the vulnerability of
272 children to onchocerciasis (6) and that men are much more exposed to the bites of simuli than
273 women, because women protect their bodies better than men and most activities near forests
274 and rivers are carried out by men. In Bossangoa district as in Kémo district, we can find many
275 activities in the forests and around rivers that expose people to the black flies propagate
276 continued transmission. Proximity to rivers breeding sites for the vector have been described to
277 influence the continued transmission of onchocerciasis by increasing exposure. Failure to take
278 ivermectin during distribution campaigns is associated with positive onchocerciasis status. Low
279 ivermectin intake was identified as a factor in the transmission of the disease. Several authors

280 have attested to this fact (28). So it is importance of improving and sustaining high therapeutic
281 coverage and increasing treatment frequency if countries are to achieve elimination of
282 onchocerciasis transmission.

283 **Strengths and limitations of study**

284 This study is not a comparison of prevalence between two onchocerciasis endemic areas, one
285 in the savannah and the other in the forest. It highlighted the particularities of transmission of
286 the disease in each of these regions, which should be taken into account in the planning of
287 control activities by the PNLOC. In addition, this study did not describe the reasons why
288 participants did not take ivermectin; this was taken into account in another study.

289 **Conclusions**

290 After more than 20 years of combating onchocerciasis through the community-based
291 distribution of ivermectin, the prevalence of this disease remains worrying in both savannah
292 and forest areas: 26.45% and 14.79% respectively. This prevalence is reduced when the
293 population adheres to taking ivermectin. The burden of onchocerciasis in endemic areas is
294 evident in skin and eye disorders. The main factors in the transmission of the disease in these
295 two areas are young age, male sex, not taking ivermectin and living near rivers. The PNLOC
296 needs to review its planning of activities, ensuring that the population is constantly made aware
297 before drugs are distributed, and increasing the number of days of community-based
298 distribution in order to improve therapeutic coverage. Finally, all activities need to be monitored
299 and evaluated.

300 **Acknowledges**

301 We would like to thank the members of the health management teams in these 2 health districts,
302 the health centre managers in these districts and the leaders of these 2 communities who helped
303 to make this study a success.

304 **Authors contribution**

305 WSH designed the study, wrote the protocol and text and supervised the data analysis. SHW, SIGA,
306 ADBN, RHDW, HSCD and JDDL participated in the drafting of the protocol, data analysis and text
307 writing. WSH coordinated all stages of the research. All authors have read and approved the manuscript
308 and contributed equally.

309 **Conflicts of interest**

310 No conflicts

311 References

312

- 313 1. Onchocercose [Internet]. [cited 2024 Jun 9]. Available from:
314 <https://www.who.int/fr/news-room/fact-sheets/detail/onchocerciasis>
- 315 2. Onchocerciasis (River Blindness) - Infectious Diseases - MSD Manual Professional
316 Edition [Internet]. [cited 2024 Jun 23]. Available from:
317 [https://www.msmanuals.com/professional/infectious-diseases/nematodes-](https://www.msmanuals.com/professional/infectious-diseases/nematodes-roundworms/onchocerciasis-river-blindness)
318 [roundworms/onchocerciasis-river-blindness](https://www.msmanuals.com/professional/infectious-diseases/nematodes-roundworms/onchocerciasis-river-blindness)
- 319 3. Kirkwood B, Smith P, Marshall T, Prost A. Relationships between mortality, visual
320 acuity and microfilarial load in the area of the Onchocerciasis Control Programme.
321 *Trans R Soc Trop Med Hyg* [Internet]. 1983 [cited 2024 Jun 23];77(6):862–8.
322 Available from: <https://pubmed.ncbi.nlm.nih.gov/6665841/>
- 323 4. Guderian RH, Lovato R, Anselmi M, Mancero T, Cooper PJ. Onchocerciasis and
324 reproductive health in Ecuador. *Trans R Soc Trop Med Hyg* [Internet]. 1997 [cited
325 2024 Jun 23];91(3):315–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/9231206/>
- 326 5. World Health Organization. L'onchocercose et la lutte anti-onchocerquienne : rapport.
327 1995;113.
- 328 6. Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al.
329 Burden and factors associated with onchocerciasis transmission among school-aged
330 children after more than 20 years of Community Directed Treatment with Ivermectin in
331 Ulanga district, Tanzania: A school-based cross-sectional study. *PLOS Glob Public*
332 *Heal*. 2023 May 12;3(5):e0001919.
- 333 7. Evans TG. Socioeconomic consequences of blinding onchocerciasis in west Africa.
334 *Bull World Health Organ* [Internet]. 1995 [cited 2024 Jun 23];73(4):495. Available
335 from: [/pmc/articles/PMC2486790/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/1041144/)
- 336 8. Sherwin JC, Lewallen S, Courtright P. Blindness and visual impairment due to
337 uncorrected refractive error in sub-Saharan Africa: Review of recent population-based
338 studies. *Br J Ophthalmol*. 2012 Jul;96(7):927–30.
- 339 9. Ahmed A, Elbashir A, Mohamed AA, Alim AA, Mubarak A, Abdelrahman D, et al.
340 Socioeconomic impacts of elimination of onchocerciasis in Abu-Hamed focus,
341 northern Sudan: Lessons after elimination. *BMC Res Notes*. 2020 May 26;13(1).
- 342 10. Colebunders R, Njamnshi AK, Menon S, Newton CR, Hotterbeekx A, Preux PM, et al.
343 *Onchocerca volvulus* and epilepsy: A comprehensive review using the Bradford Hill
344 criteria for causation. *PLoS Negl Trop Dis* [Internet]. 2021 Jan 1 [cited 2024 Jun
345 23];15(1):1–24. Available from: [/pmc/articles/PMC7790236/](https://pubmed.ncbi.nlm.nih.gov/3581144/)
- 346 11. Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis Elimination:
347 Progress and Challenges. *Res Rep Trop Med* [Internet]. 2020 Oct [cited 2024 Jun
348 23];11:81. Available from: [/pmc/articles/PMC7548320/](https://pubmed.ncbi.nlm.nih.gov/3581144/)
- 349 12. Hendy A, Krüger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et al. The blackfly
350 vectors and transmission of *Onchocerca volvulus* in Mahenge, south eastern Tanzania.

- 351 Acta Trop [Internet]. 2018 May 1 [cited 2024 Jun 20];181:50–9. Available from:
352 <https://pubmed.ncbi.nlm.nih.gov/29410302/>
- 353 13. Kelsey JL. Methods in Observational Epidemiology; Table 12-15 \r. Results from
354 OpenEpi, Version 3, open source Calc [Internet]. 1996 [cited 2024 Jun 20];10:366
355 pages. Available from: <https://search.worldcat.org/title/856808377>
- 356 14. Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H,
357 et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-
358 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet
359 (London, England) [Internet]. 2020 Oct 17 [cited 2024 Mar 12];396(10258):1204–22.
360 Available from: <https://pubmed.ncbi.nlm.nih.gov/33069326/>
- 361 15. Ending the neglect to attain the Sustainable Development Goals: A road map for
362 neglected tropical diseases 2021–2030 [Internet]. [cited 2024 Jun 24]. Available from:
363 <https://www.who.int/publications/i/item/9789240010352>
- 364 16. UNSDG | Leave No One Behind [Internet]. [cited 2024 Jun 24]. Available from:
365 <https://unsdg.un.org/2030-agenda/universal-values/leave-no-one-behind>
- 366 17. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins
367 A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for
368 Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin
369 Treatment in Africa. Clin Infect Dis An Off Publ Infect Dis Soc Am [Internet]. 2014
370 Oct 10 [cited 2024 Mar 12];59(7):923. Available from: [/pmc/articles/PMC4166981/](https://pubmed.ncbi.nlm.nih.gov/254166981/)
- 371 18. The Kigali Declaration | Uniting to Combat NTDs [Internet]. [cited 2024 Mar 12].
372 Available from: <https://unitingtocombatntds.org/en/the-kigali-declaration/>
- 373 19. Elphick-Pooley T, Engels D. World NTD Day 2022 and a new Kigali Declaration to
374 galvanise commitment to end neglected tropical diseases. Infect Dis poverty [Internet].
375 2022 Dec 1 [cited 2024 Jun 24];11(1). Available from:
376 <https://pubmed.ncbi.nlm.nih.gov/35086566/>
- 377 20. Mshana Id MI, Silvestri Id V, Id VM, Bonaventura WM, Tarimo D, Ngasala B, et al.
378 Burden and factors associated with onchocerciasis transmission among school-aged
379 children after more than 20 years of Community Directed Treatment with Ivermectin in
380 Ulanga district, Tanzania: A school-based cross-sectional study. 2023 [cited 2024 Jun
381 13]; Available from: <https://doi.org/10.1371/journal.pgph.0001919>
- 382 21. Komlan K, Vossberg PS, Gantin RG, Solim T, Korbmacher F, Banla M, et al.
383 Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and
384 parasite transmission in northern and central Togo after decades of Simulium
385 damnosum s.l. vector control and mass drug administration of ivermectin. PLoS Negl
386 Trop Dis [Internet]. 2018 Mar 1 [cited 2024 Jun 10];12(3). Available from:
387 <https://pubmed.ncbi.nlm.nih.gov/29494606/>
- 388 22. Otabil KB, Basáñez MG, Ankrah B, Bart-Plange EJ, Babae TN, Kudzordzi PC, et al.
389 Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent
390 infection in the Bono Region of Ghana: a mixed-methods study. BMC Infect Dis
391 [Internet]. 2023 Dec 1 [cited 2024 Jun 24];23(1). Available from:
392 [/pmc/articles/PMC10655298/](https://pubmed.ncbi.nlm.nih.gov/410655298/)
- 393 23. Nyagang SM, Cumber SN, Cho JF, Keka EI, Nkfusai CN, Wepngong E, et al.
394 Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after

- 395 15 years of mass drug administration with ivermectin in the Tombel Health District,
396 Cameroon. *Pan Afr Med J* [Internet]. 2020 [cited 2024 Jun 24];35. Available from:
397 [/pmc/articles/PMC7321683/](https://pubmed.ncbi.nlm.nih.gov/31314757/)
- 398 24. Cherif MS, Keita M, Dahal P, Guilavogui T, Habib Beavogui A, Diassy L, et al.
399 Neglected tropical diseases in Republic of Guinea: disease endemicity, case burden and
400 the road towards the 2030 target. *Int Health* [Internet]. 2023 [cited 2024 Jun 24];
401 Available from: <https://doi.org/10.1093/inthealth/ihad036>
- 402 25. Siewe Fodjo JN, Mandro M, Mukendi D, Tepage F, Menon S, Nakato S, et al.
403 Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical
404 description and relationship with microfilarial density. *PLoS Negl Trop Dis* [Internet].
405 2019 Jul 1 [cited 2024 Jun 24];13(7). Available from:
406 <https://pubmed.ncbi.nlm.nih.gov/31314757/>
- 407 26. Bhattacharyya S, Melchers NVSV, Fodjo JNS, Vutha A, Coffeng LE, Logora MY, et
408 al. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and
409 exploring the impact of control measures against river blindness. *PLoS Negl Trop Dis*
410 [Internet]. 2023 May 1 [cited 2024 Jun 24];17(5). Available from:
411 <https://pubmed.ncbi.nlm.nih.gov/37235598/>
- 412 27. Jada SR, Tionga MS, Siewe Fodjo JN, Carter JY, Logora MY, Colebunders R.
413 Community perception of epilepsy and its treatment in onchocerciasis-endemic villages
414 of Maridi county, western equatoria state, South Sudan. *Epilepsy Behav* [Internet].
415 2022 Feb 1 [cited 2024 Jun 24];127. Available from:
416 <https://pubmed.ncbi.nlm.nih.gov/35026562/>
- 417 28. Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis
418 transmission persists after 15 annual ivermectin mass drug administrations in South-
419 West Cameroon. *BMJ Glob Heal* [Internet]. 2021 Jan 1 [cited 2024 Jun
420 10];6(1):e003248. Available from: <https://gh.bmj.com/content/6/1/e003248>
- 421
- 422
- 423
- 424
- 425
- 426
- 427
- 428
- 429
- 430